It’s A First (And Second) For IPF: Two Drugs Approved By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved the first two drugs for the fatal lung disease idiopathic pulmonary fibrosis: Roche’s Esbriet and Boehringer Ingelheim’s Ofev. The simultaneous approvals set the stage for a commercial showdown.
You may also be interested in...
Keeping Track: Ofev Snags SSc-ILD Indication, Accelerated Approval Reviews For Veverimer And Voxelotor, J&J Gets Its First Vaccine BTD
The latest drug development news and highlights from our US FDA Performance Tracker.
Boehringer's Ofev Faces Efficacy Hurdle For SSc-ILD Indication At US FDA Advisory Cmte.
The Arthritis Advisory Committee will give its take on Boehringer Ingelheim's forced vital capacity data as the drugmaker seeks to land add an indication for a rare lung disease to the label of its tyrosine kinase inhibitor Ofev.
Keeping Track: Thumbs Up For Zulresso And Sunosi, Thumbs Down For Zynquista And IV Meloxicam
The latest drug development news and highlights from our US FDA Performance Tracker.